1-3 of 3
Peter Daniel, MD
Close
Sort by
Journal Articles

Increased MSI2 expression Is Associated with Aggressive CML and AML

Jaspal S Kaeda, PhD, FRCPath, Ken I. Mills, PhD, FRCPath, Michael G Kharas, PhD, Giuseppe Saglio, MD, Michaela Schwarz, MD, Christian Oberender, Bärbel Pawlaczyk-Peter, Antje van Lessen, Seval Türkmen, MD, Claudia D Baldus, MD, Frauke Ringel, PhD, Thomas Pretzsch, Peggy Grille, Anna Serra, PhD, Anne Carson, PhD, Mary Frances McMullin, MD, Jörg Westermann, MD, Peter Daniel, MD, PhD, Bernd Dörken, Philipp D. le Coutre, MD
Journal: Blood
Blood (2011) 118 (21): 2516.
https://doi.org/10.1182/blood.V118.21.2516.2516
Published: 2011
Journal Articles

Long-Term Follow-up of Philadelphia Chromosome-Positive Chronic Myeloid Leukemia Patients After Stem Cell Mobilisation Under Imatinib.

Theo D. Kim, MD, Michaela Schwarz, MD, Karl-Anton Kreuzer, MD, Jaspal Kaeda, PhD, Kamran Movassaghi, MD, Peggy Grille, Peter Daniel, MD, PhD, Bernd Dörken, Philipp le Coutre
Journal: Blood
Blood (2010) 116 (21): 3418.
https://doi.org/10.1182/blood.V116.21.3418.3418
Published: 2010
Journal Articles

Bcr-Abl and Wilms Tumor Gene (WT1) Kinetics in Nilotinib (AMN107) Treated CML Patients.

Michaela Schwarz, MD, Gokben Baskaynak, MD, Seval Turkmen, MD, Peter Schuld, MD, Bernd Dorken, MD, Peter Daniel, MD, le Coutre Philipp
Journal: Blood
Blood (2006) 108 (11): 2336.
https://doi.org/10.1182/blood.V108.11.2336.2336
Published: 2006